Unlabeled Uses:
Contraindicated in:
Use Cautiously in:
Exercise Extreme Caution in:
CV: hypertension, hypotension.
Derm: maculopapular rash, flushing.
EENT: blurred vision, ↓ hearing, diplopia, lens opacities, optic neuritis, toxic retinopathy.
Endo: adrenal suppression, gynecomastia.
GI: anorexia, diarrhea, nausea, vomiting, ↑ salivation.
GU: albuminuria, hematuria, hemorrhagic cystitis, ovarian macrocysts.
Hemat: ↑bleeding time.
Metab: hypercholesterolemia, hypouricemia.
MS: arthralgia, myalgia.
Neuro: lethargy, somnolence, brain damage, dizziness, fatigue, functional impairment (high-dose, long-term therapy), headache, irritability, mental depression, tremors, vertigo, weakness.
Drug-Drug:
Adrenocortical Carcinoma
Cushings Syndrome
Absorption: 3040% absorbed following oral administration.
Distribution: Widely distributed to all body tissues; accumulates in fatty tissue.
Metabolism/Excretion: Slowly released from fatty tissue. Mostly metabolized by the liver; 10% excreted by the kidneys; 15% excreted in bile.
Half-life: 18159 days.
(clinical effects)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | 24 wk | 6 wk | unknown |
Onset = inhibition of adrenocortical function; peak = tumor response.